MedTrace Logo

CRF2 Agonist for the Treatment of Worsening Heart Failure

NCT06815471 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-08

No results posted yet for this study

Summary

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Conditions

  • Worsening Heart Failure

Interventions

DRUG

COR-1167

28-day treatment

DRUG

Placebo

28-day treatment

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • Corteria Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jeffrey Testani, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-07
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Georgia
  • Hungary
  • Poland
  • Romania
  • Serbia
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06815471 on ClinicalTrials.gov